TBN
TuBerculosis News

NOVEMBER 2013

MEDICI CON L'AFRICA
CUAMM
Doctors with Africa

Research

DIAGNOSTIC

- QuantuMDx Gets $1.6M from UK Government for Drug-resistant TB Test
- Pocket' project aims to develop TB sensor that fits in your pocket
- Xpert MTB/RIF version G4 for the identification of rifampicin resistant tuberculosis in a programmatic setting- JCM- RESEARCH
- Pyrosequencing for Rapid Detection of Extensively Drug-Resistant Tuberculosis in Clinical Isolates and Clinical Specimens.- JCM- RESEARCH
- miRNA Signatures in Sera of Patients with Active Pulmonary Tuberculosis..- PLose One- RESEARCH
- DNA probe based colorimetric method for detection of rifampicin resistance of Mycobacterium tuberculosis..- JMM- RESEARCH
- Evaluation of the FluoroType MTB assay for the rapid and reliable detection of Mycobacterium tuberculosis in respiratory tract specimens..- Clin Lab- RESEARCH
- Evaluation of a Simple in-House Test to Presumptively Differentiate Mycobacterium tuberculosis Complex from Nontuberculous Mycobacteria by Detection of p-Nitrobenzoic Acid Metabolites PLose One- RESEARCH
- Efficacy of IP-10 as a biomarker for monitoring tuberculosis treatment -J infect- RESEARCH
- Pyrosequencing for Rapid Detection of Extensively Drug-Resistant Tuberculosis in Clinical Isolates and Clinical Specimens- J Clin Microbiol - RESEARCH
- Rapid Molecular Testing for TB to Guide Respiratory Isolation in the U.S.: A Cost-Benefit Analysis. - PLose One- RESEARCH

VACCINE

- Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7)RESEARCH
- First results tuberculosis vaccine candidate MTBVAC very promising
- SSI and Aeras announce initiation of Phase I/IIa clinical trial for TB vaccine candidate
- TB vaccine failure was predictable. Nature

DRUGS

- VapC20 of Mycobacterium tuberculosis cleaves the Sarcin–Ricin loop of 23S rRNA- Nature- RESEARCH
- Ethambutol resistance determined by broth dilution method better correlates with embB mutations in MDR tuberculosis isolates- J Clin Microbiol - RESEARCH
- A natural antibiotic turns out to be a lethal weapon in the fight against tuberculosis. Scientists have discovered it has an unexpected dual action that dramatically reduces the probability that TB bacteria will become resistant
  - Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA - Nature-RESEARCH

Implementation of control

EUROPEAN REGION

- Belarus: standards of care rise, TB disease and deaths decline
- UK
  - Diagnosis and treatment of tuberculosis worldwide: UK Parliament
  - UK patients with MDR-TB have good outcomes but a quarter not receiving the recommended duration of therapy

SOUTH-EST ASIA REGION

- INDIA
  - When will India eradicate tuberculosis?
- TB Prize Selection Gets Caught in Politics

WESTERN PACIFIC REGION

- Japanese Fund Moves Quickly to Invest in Promising Technology Against Malaria, Tuberculosis And Chagas Disease

WHO

- WHO EUROPE
  - New collaborating committee on tuberculosis control and care: RCC-TB
  - Regional workshop on ethics and human right for prevention and care of M/XDR-TB
  - Regional workshop on models of care of TB and M/XDR-TB
  - European TB Conference 2013
- Dr. M Raviglione talk about the #WHO #UNITAID #TBXpert project-why it was started and sustainability plans
- PPT Dr. Raviglione.Paris_TBVI_Symposium_10-2013
- Tuberculosis laboratory biosafety manual. Published in 6 languages
- Put in more money to tackle tuberculosis: Dr Mario Raviglione, the director of World Health Organization's Global Tuberculosis Programme
- European Medicines Agency recommends two new treatment options for tuberculosis: Conditional marketing authorisation recommended for Deltyba
  - WHO: Information note on the use of a new agent, delamanid, for the treatment of multidrug-resistant tuberculosis
- Guidance for Development of National Laboratory Strategic Plans

TB INNOVATION Blog

- WHO Global Tuberculosis Report 2013: priorities to sustain progress and achieve TB control.

ECDC

- Epidemiological situation of HIV and tuberculosis and most affected populations in the Northern Dimension countries

Highlights from the Global Fund's replenishment

- EU invests €8.5 million in the fight against poverty related diseases
- U.S. will match contributions to the Global Fund, up to $5 billion over three years
- Canada invests CAN $650 million in the fight against poverty related diseases
- Japan committed US $800 million.
- France committed €1.08 billion
- Australia has pledged AUD $200 million over the next three years
- The United Kingdom made a historic commitment of up to £1 billion
- $1,4 billion funding shortfall for tuberculosis control Lancet
- New Anti-TB Strategy Target: Elimination of the Disease